Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T18:56:30.521Z.
Calculation as of: 2026-10-06T18:56:30.521Z.
Quote observation: 2026-10-06T18:26:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 015f4768d679608bc4b6bcfba81ca244afda57a14a617ca6285ea64adc9468bc
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Drugs Made In America Acquisition Corp. Ordinary Shares
Market Cap
$264.38M
EV/Sales Ratio
N/A
Market Cap
$261.73M
EV/Sales Ratio
N/A
| NAME | MARKET CAP | EV/SALES RATIO |
|---|---|---|
| Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) | $264.38M | N/A |
| ProCap Acquisition Corp (PCAP)vs › | $264.47M | N/A |
| Oaktree Acquisition Corp. II (OACC)vs › | $264.51M | N/A |
| Hawthorn Bancshares, Inc. (HWBK)vs › | $265.12M | N/A |
| Soren Acquisition Corp. (SORN)vs › | $263.53M | N/A |
| Thunder Bridge Capital Partners V L (TBCVU)vs › | $266.29M | N/A |
| Translational Development Acquisition Corp. (TDAC)vs › | $266.99M | N/A |
| AMR Resources Acquisition Corp Class A Ordinary Shares (AMAC)vs › | $261.73M | N/A |
| GigCapital8 Corp. (GIW)vs › | $261.45M | N/A |
| Cantor Equity Partners V, Inc. Class A Ordinary Shares (CEPV)vs › | $261.27M | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
